Key result
A single bolus of enoxaparin (60 IU/kg) in haemodialysis patients resulted in anti-Xa activity remaining >0.4 IU/ml up to 10 hours and >0.1 IU/ml up to 24 hours after injection.
Why the study?
What is the duration of anticoagulation after bolus administration of enoxaparin at the start of haemodialysis in chronic haemodialysis patients?
Observational (n=30)
What is the duration of anticoagulation after bolus administration of enoxaparin at the start of haemodialysis in chronic haemodialysis patients?
A single bolus of enoxaparin at the start of haemodialysis results in prolonged anti-Xa activity, placing patients at risk of bleeding for up to 10 hours post-injection.
Answers are grounded in this paper and cite their sources.
May heighten bleeding risk up to 10 hours post-bolus in haemodialysis; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: The interest of low molecular weight heparins (LMWH) regarding bleeding risk is controversial in renal failure patients. In haemodialysis patients, there are very few data on the pharmacokinetics of LMWH after the end of the session. The aim of the study was to evaluate the duration of anticoagulation after bolus administration of the LMWH enoxaparin at the start of haemodialysis. METHODS: The pharmacokinetics of enoxaparin were studied during the 48 h following a single bolus injection at the start of the dialysis session in 30 chronic haemodialysis patients. Pharmacokinetics were determined using a population approach (Non Linear Mixed Effects Modelling). RESULTS: A single injection of enoxaparin at 60 U IU/kg (4000 +/- 455 IU) led to an anti-Xa activity higher than 1.2 IU/ml during the first 2 h of the session, and between 0.4 and 1.2 IU during the third and fourth hours. After the end of the session, anti-Xa activity remained higher than 0.4 IU/ml up to 10 h after injection, and higher than 0.1 IU/ml up to 24 h. The pharmacokinetic model showed that only weight improved the predicted vs observed anti-Xa activity plot. The model was used to simulate single and multiple dosing with decreased enoxaparin doses. Whatever the procedure, anti-Xa activity remained high (>0.22 +/- 0.99 UI/ml) up to 12 h after the start of the dialysis session. CONCLUSIONS: These results suggest that haemodialysis patients receiving the LMWH enoxaparin during dialysis are at risk of bleeding up to 10 h after the injection.
No takes yet. Share an insight, caveat, or question.
Benjamin Guillet (2003) conducted an observational in Chronic haemodialysis (n=30). Enoxaparin was evaluated on Anti-Xa activity (pharmacokinetics). A single bolus of enoxaparin (60 IU/kg) in haemodialysis patients resulted in anti-Xa activity remaining >0.4 IU/ml up to 10 hours and >0.1 IU/ml up to 24 hours after injection.
Synapse has enriched 10 related papers. Consider them for comparative context: